Table 7.
Regression analysis of factors influencing H. pylori eradication rates.
| Variables | Eradication success (n=458) | Eradication failure (n=54) | P-value |
|---|---|---|---|
| Sex (Male/Female) | 221/237 | 22/32 | 0.297 |
| Age (years) | 48.57 ± 12.62 | 49.43 ± 11.44 | 0.633 |
| BMI (kg/m2) | 23.65 ± 3.34 | 23.91 ± 3.34 | 0.589 |
| Medical history | |||
| Hypertension | 84 (18.3%) | 6 (11.1%) | 0.193 |
| Diabetes | 31 (6.8%) | 6 (11.1%) | 0.248 |
| Hyperlipidemia | 34 (7.4%) | 3 (5.6%) | 0.617 |
| Coronary Heart Disease | 8 (1.7%) | 0 | 0.622 |
| Other | 53 (11.6%) | 7 (13.0%) | 0.764 |
| Smoking history | 120 (26.2%) | 12 (22.2%) | 0.528 |
| Alcohol consumption | 173 (37.8%) | 20 (37.0%) | 0.914 |
| Previous eradication therapy | 27 (5.9%) | 4 (7.4%) | 0.660 |
| Recent Gastrointestinal Symptoms | 197 (43.0%) | 19 (35.2%) | 0.273 |
| Antibiotic use in past 2 years | |||
| Amoxicillin/Penicillin | 129 (28.2%) | 17 (31.5%) | 0.609 |
| Clarithromycin | 23 (5.0%) | 2 (3.7%) | 0.672 |
| Metronidazole/Tinidazole | 24 (5.2%) | 1 (1.9%) | 0.297 |
| Levofloxacin | 60 (13.1%) | 7 (13.0%) | 0.978 |
| Furazolidone | 2 (0.4%) | 0 | 0.740 |
| Tetracycline | 2 (0.4%) | 0 | 0.740 |
| Cephalosporin | 150 (32.8%) | 10 (18.5%) | 0.036 |
| Other/Unknown | 50 (10.9%) | 7 (13.0%) | 0.651 |
| Adverse Effects | 65 (14.2%) | 10 (18.5%) | 0.397 |
H. pylori, Helicobacter pylori; BMI, body mass index.